Skip to main navigation
Skip to search
Skip to main content
WashU Medicine Research Profiles Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Diurnal cortisol and survival in epithelial ovarian cancer
Andrew Schrepf
,
Premal H. Thaker
, Michael J. Goodheart
, David Bender
, George M. Slavich
, Laila Dahmoush
, Frank Penedo
, Koen DeGeest
, Luis Mendez
, David M. Lubaroff
, Steven W. Cole
, Anil K. Sood
, Susan K. Lutgendorf
Division of Gynecologic Oncology
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center
Research output
:
Contribution to journal
›
Article
›
peer-review
91
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Diurnal cortisol and survival in epithelial ovarian cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Cortisol
100%
Epithelial Ovarian Cancer
100%
Diurnal Cortisol
100%
Hypothalamic-pituitary-adrenal
60%
Inflammation
40%
Ovarian Cancer
40%
Tumor Inflammation
40%
Tumor
20%
Clinical Significance
20%
Cox Proportional Hazards Regression Analysis
20%
Interleukin-6
20%
Disease Severity
20%
Dysregulation
20%
Advanced Disease
20%
Tumor Grade
20%
In Cancer
20%
Cancer Patients
20%
Adjusting for Covariates
20%
Ascitic Fluid
20%
Ovarian Cancer Patients
20%
Survival Time
20%
Disease Stage
20%
Cytoreduction
20%
Circadian Disruption
20%
Deregulation
20%
Non-invasive Measurement
20%
Cortisol Slope
20%
Adrenal Activity
20%
Hypothalamic-pituitary-adrenal Function
20%
Salivary Cortisol
20%
Endogenous Control
20%
Slope Variability
20%
Medicine and Dentistry
Hydrocortisone
100%
Krukenberg Tumor
100%
Neoplasm
33%
Ovarian Cancer
33%
Diseases
22%
Malignant Neoplasm
11%
Disease Severity
11%
Proportional Hazards Model
11%
Interleukin 6
11%
Adrenal Function
11%
Clinical Significance
11%
Cancer Staging
11%
Rhythm
11%
Survival Time
11%
Ascites Fluid
11%
Pharmacology, Toxicology and Pharmaceutical Science
Hydrocortisone
100%
Ovary Carcinoma
100%
Inflammation
44%
Neoplasm
33%
Ovary Cancer
33%
Diseases
22%
Malignant Neoplasm
11%
Disease Severity
11%
Interleukin 6
11%
Survival Time
11%
Cancer Staging
11%
Ascites
11%